The capital raise was completed in partnership with global alternative asset management firm TPH.
Image credit: AdobeStock/Kiattisak
Global ophthalmic device company BVI Medical has announced the completion of its $1 billion strategic capital raise in partnership with global alternative asset management firm TPH. The investment fully refinanced BVI’s existing debt and added new equity from both TPG and new investors.1 The company plans to continue substantial growth in its portfolio of product offerings in light of the investment, according to a news release.
“This investment marks a pivotal moment for BVI as we scale our capabilities to meet the rising demand for advanced ophthalmic solutions,” said Shervin Korangy, president and CEO of BVI, in the release. “We are redefining the future of eye surgery and changing the competitive landscape by driving the launch of breakthrough technologies that will empower surgeons worldwide.”
Of recent note, BVI expanded its IOL manufacturing to Europe in order to meet global product demand, introduced new product lines including SERENITY and SERENITY Toric premium monofocal IOLs,2 and has engaged in a number of strategic acquisitions. Additionally, the company launched an education platform for ophthalmologists earlier this year, which allows physicians to connect across specialties to share insights and address complex cases.3
“TPG is proud to continue our partnership with BVI as it works to scale its global impact in ophthalmic care,” said Kendall Garrison, Partner at TPG. “The company has strengthened its market position while advancing patient care worldwide and this investment will further drive innovation and expansion. We look forward to supporting BVI’s continued success,” added John Schilling, MD, Co-Managing Partner at TPG Capital.